The first U.S. human trial using CRISPR to treat disease could kick off any day now. The trial is led by the University of Pennsylvania. It will use the gene-editing tool to modify immune cells, prompting them to attack three different types of cancer.<br />A spokesperson from Penn Medicine confirmed to Gizmodo that trial preparations are in the final stages. It did not specify when exactly it will start.<br />The study will enroll as many as 18 patients with myeloma, sarcoma, and melanoma cancers. <br />
